Impact of extra treatment after surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at whether additional treatment after liver surgery (like chemotherapy or radiation) can help people with a rare and aggressive liver cancer called primary hepatic sarcomatoid carcinoma (PHSC). It only includes people who had surgery and no other cancer treatments before that.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove part or all of your liver.
- Your doctors confirmed the cancer is a rare type called primary hepatic sarcomatoid carcinoma (PHSC) based on your post-surgery tissue sample.
- You did not receive any other cancer treatments (like ablation, chemoembolization, radiation, or systemic therapy) before your liver surgery.
- You do not have another type of sarcoma or other active cancer.
- You have complete medical records available and are not lost to follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving an immunotherapy drug after surgery can help prevent liver cancer from coming back. The drug works by helping your immune system fight any remaining cancer cells.
This trial tests whether giving additional treatment after a liver transplant can help prevent liver cancer from coming back in people who are at high risk for recurrence. The treatment is given shortly after the transplant and aims to improve outcomes for patients with aggressive liver cancer.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
This trial studies giving targeted radiation after a liver procedure called trans-arterial chemoembolization for hepatocellular carcinoma (HCC). It may help control the cancer in people who cannot have surgery or transplant.
This trial looks at how well certain initial treatments (like targeted therapy, immunotherapy, or liver-directed procedures) work in people with liver cancer who have not had surgery yet. It aims to see if these treatments can shrink the tumor enough to allow removal later.
This trial tests a combination of three drugs given before and after surgery for liver cancer that can be removed. The goal is to see if this approach can help reduce the chance of the cancer coming back.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.